|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Influence of gut microbiota on neuropsychiatric disorders显示文摘The last decade has witnessed a growing appreciation of the fundamental role played by an early assembly of a diverse and balanced gut microbiota and its subsequent maintenance for future health of the host. Gut microbiota is currently viewed as a key regulator of a fluent bidirectional dialogue between the gut and the brain(gut-brain axis). A number of preclinical studies have suggested that the microbiota and its genome(microbiome) may play a key role in neurodevelopmental and neurodegenerative disorders. Furthermore, alterations in the gut microbiota composition in humans have also been linked to a variety of neuropsychiatric conditions, including depression, autism and Parkinson's disease. However, it is not yet clear whether these changes in the microbiome are causally related to such diseases or are secondary effects thereof. In this respect, recent studies in animals have indicated that gut microbiota transplantation can transfer a behavioral phenotype, suggesting that the gut microbiota may be a modifiable factor modulating the development or pathogenesis of neuropsychiatric conditions. Further studies are warranted to establish whether or not the findings of preclinical animal experiments can be generalized to humans. Moreover, although different communication routes between the microbiota and brain have been identified, further studies must elucidate all the underlying mechanisms involved. Such research is expected to contribute to the design of strategies to modulate the gut microbiota and its functions with a view to improving mental health, and thus provide opportunities to improve the management of psychiatric diseases. Here, we review the evidence supporting a role of the gut microbiota in neuropsychiatric disorders and the state of the art regarding the mechanisms underlying its contribution to mental illness and health. We also consider the stages of life where the gut microbiota is more susceptible to the effects of environmental stressors, and the possible microbiota-targeted intervention strategies that could improve health status and prevent psychiatric disorders in the near future. | María Carmen Cenit Yolanda Sanz Pilar Codoner-Franch | 2017 | World Journal of Gastroenterology2017，23，30： | 21 |
| 2 | 在没有危险因素的情况下,正常的低密度脂蛋白胆固醇水平与亚临床动脉粥样硬化相关显示文摘普遍认为缺乏心血管病危险因素(cardiovascular risk factors,CVRF)人群的动脉粥样硬化发生风险低,然而,无CVRF的个体仍然有心血管事件发生。为了确定无CVRF个体中亚临床动脉粥样硬化的预测因子, | Fernández-Friera L Fuster V López-Melgar B Oliva B García-Ruiz JM Mendiguren J Bueno H Pocock S Ibánez B Fernández-Ortiz A Sanz J 刘莉 叶鹏 | 2017 | 中华高血压杂志2017，25，12： | 17 |
| 3 | Gut bless you:The microbiota-gut-brain axis in irritable bowel syndrome显示文摘Irritable bowel syndrome(IBS)is a common clinical label for medically unexplained gastrointestinal symptoms,recently described as a disturbance of the microbiota-gut-brain axis.Despite decades of research,the pathophysiology of this highly heterogeneous disorder remains elusive.However,a dramatic change in the understanding of the underlying pathophysiological mechanisms surfaced when the importance of gut microbiota protruded the scientific picture.Are we getting any closer to understanding IBS’etiology,or are we drowning in unspecific,conflicting data because we possess limited tools to unravel the cluster of secrets our gut microbiota is concealing?In this comprehensive review we are discussing some of the major important features of IBS and their interaction with gut microbiota,clinical microbiota-altering treatment such as the low FODMAP diet and fecal microbiota transplantation,neuroimaging and methods in microbiota analyses,and current and future challenges with big data analysis in IBS. | Eline Margrete Randulff Hillestad Aina van der Meeren Bharat Halandur Nagaraja Ben RenéBjørsvik Noman Haleem Alfonso Benitez-Paez Yolanda Sanz Trygve Hausken Gülen Arslan Lied Arvid Lundervold Birgitte Berentsen | 2022 | World Journal of Gastroenterology2022，28，4： | 15 |
| 4 | Gut microbiota-related complications in cirrhosis显示文摘Gut microbiota plays an important role in cirrhosis. The liver is constantly challenged with commensal bacteria and their products arriving through the portal vein in the so-called gut-liver axis. Bacterial translocation from the intestinal lumen through the intestinal wall and to mesenteric lymph nodes is facilitated by intestinal bacterial overgrowth, impairment in the permeability of the intestinal mucosal barrier, and deficiencies in local host immune defences. Deranged clearance of endogenous bacteria from portal and systemic circulation turns the gut into the major source of bacterialrelated complications. Liver function may therefore be affected by alterations in the composition of the intestinal microbiota and a role for commensal flora has been evidenced in the pathogenesis of several complications arising in end-stage liver disease such as hepatic encephalopathy, splanchnic arterial vasodilatation and spontaneous bacterial peritonitis. The use of antibioticsis the main therapeutic pipeline in the management of these bacteria-related complications.However,other strategies aimed at preserving intestinal homeostasis through the use of pre-,pro-or symbiotic formulations are being studied in the last years.In this review,the role of intestinal microbiota in the development of the most frequent complications arising in cirrhosis and the different clinical and experimental studies conducted to prevent or improve these complications by modifying the gut microbiota composition are summarized. | Isabel Gómez-Hurtado José Such Yolanda Sanz Rubén Francés | 2014 | World Journal of Gastroenterology2014，20，42： | 12 |
| 5 | 牙周疾病与心血管疾病的相关性显示文摘 | Mariano Sanz Francesco D' Aiuto John Deanfield Francisco Fernandez-Avilés 陈明 谢良地 | 2010 | 中华高血压杂志2010，18，7： | 5 |
| 6 | Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?显示文摘Chronic hepatitis B(CHB) remains a challenging global health problem, with nearly one million related deaths per year. Nucleos(t)ide analogue(NA) treatment suppresses viral replication but does not provide complete cure of the hepatitis B virus(HBV) infection. The accepted endpoint for therapy is the loss of hepatitis B surface antigen(HBs Ag), but this is hardly ever achieved. Therefore, indefinite treatment is usually required. Many different studies have evaluated NA therapy discontinuation after several years of NA treatment and before HBs Ag loss. The results have indicated that the majority of patients can remain off therapy, with some even reaching HBs Ag seroconversion. Fortunately, this strategy has proved to be safe, but it is essential to consider the risk of liver damage and other comorbidities and to ensure aclose follow-up of the candidates before considering this strategy. Unanswered questions remain, namely in which patients could this strategy be effective and what is the optimal time point at which to perform it. To solve this enigma, we should keep in mind that the outcome will ultimately depend on the equilibrium between HBV and the host's immune system. Viral parameters that have been described as good predictors of response in HBe Ag(+) cases, have proven useless in HBe Ag(-) ones. Since antiviral immunity plays an essential role in the control of HBV infection, we sought to review and explain potential immunological biomarkers to predict safe NA discontinuation in both groups. | Elia Moreno-Cubero Robert T Sánchez del Arco Julia Pena-Asensio Eduardo Sanz de Villalobos Joaquín Míquel Juan Ramón Larrubia | 2018 | World Journal of Gastroenterology2018，24，17： | 5 |
| 7 | 磺酸多相催化剂用于二甲基亚砜中C_6-单糖脱水制5-羟甲基糠醛(英)显示文摘Sulfonic acid-functionalized heterogeneous catalysts have been evaluated in the catalytic dehydration of C(,monosaccharides into 5-hydroxymethylfurfural(HMF) using dimethyl sulfoxide(DMSO)as solvent.Sulfonic commercial resin Amberlyst-70 was the most active catalyst,which was ascribed to its higher concentration of sulfonic acid sites as compared with the other catalysts,and it gave 93 mol%yield of HMF from fructose in 1 h.With glucose as the starting material,which is a much more difficult reaction,the reaction conditions(time,temperature,and catalyst loading) were optimized for Amberlyst-70 by a response surface methodology,which gave a maximum HMF yield of 33 mol%at 147 °C with 23 wt%catalyst loading based on glucose and 24 h reaction time.DMSO promotes the dehydration of glucose into anhydroglucose,which acts as a reservoir of the substrate to facilitate the production of HMF by reducing side reactions.Catalyst reuse without a regeneration treatment showed a gradual but not very significant decay in catalytic activity. | Gabriel Morales Juan A.Melero Marta Paniagua Jose Iglesias Blanca Hernandez Maria Sanz | 2014 | 催化学报2014，35，5： | 4 |
| 8 | Persistent hepatitis C virus (HCV) infection impairs HCV‐specific cytotoxic T cell reactivity through Mcl‐1/Bim imbalance due to CD127 down‐regulation显示文摘 | J. R. Larrubia M. U. Lokhande S. García‐Garzón J. Miquel A. González‐Praetorius T. Parra‐Cid E. Sanz‐de‐Villalobos | 2012 | Journal of Viral Hepatitis2012，，2： | 3 |
| 9 | Inhibition of p53 inhibitors:progress,challenges and perspectives显示文摘p53 is the major tumor suppressor and the most frequently inactivated gene in cancer.p53 could be disabled either by mutations or by upstream negative regulators,including,but not limited to MDM2 and MDMX.p53 activity is required for the prevention as well as for the eradication of cancers.Restoration of p53 activity in mouse models leads to the suppression of established tumors of different origin.These findings provide a strong support to the anti-cancer strategy aimed for p53 reactivation.In this review,we summarize recent progress in the development of small molecules,which restore the tumor suppressor function of wild-type p53 and discuss their clinical advance.We discuss different aspects of p53-mediated response,which contribute to suppression of tumors,including non-canonical p53 activities,such as regulation of immune response.While targeting p53 inhibitors is a very promising approach,there are certain limitations and concerns that the intensive research and clinical evaluation of compounds will hopefully help to overcome. | Gema Sanz Madhurendra Singh Sylvain Peuget Galina Selivanova | 2019 | Journal of Molecular Cell Biology2019，11，7： | 3 |
| 10 | Feasibility, safety, acceptability, and yield of office-based, screening transnasal esophagoscopy (with video)显示文摘 | Anne F. Peery Toshitaka Hoppo Katherine S. Garman Evan S. Dellon Norma Daugherty Susan Bream Alejandro F. Sanz Jon Davison Melissa Spacek Diane Connors Ashley L. Faulx Amitabh Chak James D. Luketich Nicholas J. Shaheen Blair A. Jobe | 2012 | Gastrointestinal Endoscopy2012，，5： | 2 |
| 11 | 孕妇使用选择性5-羟色氨重吸收抑制剂与新生儿停药综合征的关系:数据库资料分析 | Sanz E.J. De- las- Cuevas C. Kiuru A. 张剑萍 | 2005 | 世界核心医学期刊文摘(妇产科学分册)2005，0，7： | 2 |
| 12 | Commensal and probiotic bacteria influence intestinal barrier function and susceptibility to colitis in Nod1<sup>?/?</sup>;Nod2<sup>?/?</sup> Mice显示文摘 | Jane M.M. Natividad Valerie Petit Xianxi Huang Giada de Palma Jennifer Jury Yolanda Sanz Dana Philpott Clara L. Garcia Rodenas Kathy D. McCoy Elena F. Verdu | 2011 | Inflamm Bowel Dis2011，，8： | 2 |
| 13 | Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study显示文摘 | Pierre Fenaux Ghulam J Mufti Eva Hellstrom-Lindberg Valeria Santini Carlo Finelli Aristoteles Giagounidis Robert Schoch Norbert Gattermann Guillermo Sanz Alan List Steven D Gore John F Seymour John M Bennett John Byrd Jay Backstrom Linda Zimmerman David M | 2009 | Lancet Oncology2009，，： | 2 |
| 14 | Kinetics of the acid leaching of palygorskite:influence of the octahedral sheet composition显示文摘 | CORMA A MIFSUD A SANZ E | 1990 | Clay Miner1990，25，： | 2 |
| 15 | Supercritical water oxidation process under energetically self-sufficient operation 显示文摘 | Cocero M J Alonso E Sanz M T | 2002 | Journal of Supercritical Fluids2002，24，1： | 2 |
| 16 | Study of photodegradation of the pefticide ethiofencarb in aqueous and non - aqueous media, by gas chromatograghy - mass spectrometry 显示文摘 | J Sanze - Asensio M Plaza - Medina M T Martinez - Soria M Perez -Clavijo | 1999 | Journal of Chromatograghy A1999，84，： | 2 |
| 17 | Protective effect of Bifidobacterium pseudocatenulatum CECT 7765 against induced bacterial antigen translocation in experimental cirrhosis显示文摘 | Alba Moratalla Isabel Gómez‐Hurtado Arlette Santacruz ángela Moya Gloria Peiró Pedro Zapater José M. González‐Navajas Paula Giménez José Such Yolanda Sanz Rubén Francés | 2014 | Liver Int2014，，6： | 2 |
| 18 | Assessment of myocardial perfusion and viability from routine contrast-enhanced 16-detector-row computed tomography of the heart: preliminary results显示文摘 | Konstantin Nikolaou Javier Sanz Michael Poon Bernd J. Wintersperger Bernd Ohnesorge Teresa Rius Zahi A. Fayad Maximilian F. Reiser Christoph R. Becker | 2005 | European Radiology2005，，5： | 2 |
| 19 | 均相介质中脂肪酶催化沙丁鱼油甘油解反应的动力学研究(英文)显示文摘多不饱和脂肪酸(PUFAs)的生产多集中在酶催化,与无机催化相比,酶催化具有定向性和更温和的反应条件,因而酶催化制取多不饱和脂肪酸的路线在最近几年引起人们极大的兴趣。本文以优化量的叔丁醇为有机溶剂,研究了脂肪酶Lipozymeò435催化沙丁鱼油甘油解反应生成PUFA (多以甘油一酯或二酯(DAGs, MAGs)的形式存在)。首先分析了反应系统的传质影响,考察了脂肪酶载量、温度和进料浓度等因素的影响。采用一个基于甘油酯甘油解和水解这对可逆基元反应的半经验动力学模型,成功地关联了实验的动力学数据。结果表明,温度为323 K,甘油与油的摩尔比为3:1时,生成的MAG可达84 wt%以上。还考察了其他甘油解体系,并在MAG收率、反应速率和动力学参数意义等方面进行了比较。 | Angela García Solaesa María Teresa Sanz Sagrario Beltrán Rodrigo Melgosa | 2016 | Chinese Journal of Catalysis2016，37，4： | 2 |
| 20 | EU-Citizen.Science:A Platform for Mainstreaming Citizen Science and Open Science in Europe显示文摘Citizen Science(CS)is a prominent field of application for Open Science(OS),and the two have strong synergies,such as:advocating for the data and metadata generated through science to be made publicly available[1];supporting more equitable collaboration between different types of scientists and citizens;and facilitating knowledge transfer to a wider range of audiences[2].While primarily targeted at CS,the EU-Citizen.Science platform can also support OS.One of its key functions is to act as a knowledge hub to aggregate,disseminate and promote experience and know-how;for example,by profiling CS projects and collecting tools,resources and training materials relevant to both fields.To do this,the platform has developed an information architecture that incorporates the public participation in scientific research(PPSR)-Common Conceptual Model.This model consists of the Project Metadata Model,the Dataset Metadata Model and the Observation Data Model,which were specifically developed for CS initiatives.By implementing these,the platform will strengthen the interoperating arrangements that exist between other,similar platforms(e.g.,BioCollect and SciStarter)to ensure that CS and OS continue to grow globally in terms of participants,impact and fields of application. | Katherin Wagenknecht Tim Woods Francisco García Sanz Margaret Gold Anne Bowser Simone Rüfenacht Luigi Ceccaroni Jaume Piera | 2021 | Data Intelligence2021，3，1： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员